Regimen D
Sponsors
GlaxoSmithKline, Pearl Therapeutics, Inc.
Conditions
CancerChronic Obstructive Pulmonary Disease
Phase 1
An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor
CompletedNCT01231568
Start: 2010-10-21End: 2011-05-13Updated: 2017-11-14
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
CompletedNCT03311373
Start: 2017-10-17End: 2017-12-15Updated: 2020-06-11